Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?

PubWeight™: 1.55‹?› | Rank: Top 4%

🔗 View Article (PMC 2360106)

Published in Br J Cancer on February 27, 2007

Authors

H Uramoto1, T Mitsudomi

Author Affiliations

1: Cancer Chemotherapy Center, University of Occupational and Environmental Health, Japan.

Articles citing this

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79

Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer (2007) 1.87

Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One (2011) 1.65

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44

In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer. PLoS One (2016) 1.38

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol (2011) 1.31

Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS One (2013) 1.13

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn (2008) 1.11

Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer (2008) 1.11

Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J (2009) 1.10

EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol (2009) 1.03

Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov (2010) 1.02

Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer (2010) 1.02

Generation of a non-small cell lung cancer transcriptome microarray. BMC Med Genomics (2008) 1.01

Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch (2010) 0.98

The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res (2009) 0.96

Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol (2008) 0.88

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer (2008) 0.87

Investigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression. Oncol Lett (2014) 0.86

A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. Curr Oncol (2012) 0.86

Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report. Respir Med Case Rep (2013) 0.82

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients. J Transl Med (2011) 0.82

Lung cancer in never smokers. Semin Respir Crit Care Med (2011) 0.81

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Cancer Res (2015) 0.81

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol (2009) 0.80

Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment. BMC Pulm Med (2016) 0.77

Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs. PLoS One (2016) 0.76

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Front Oncol (2017) 0.75

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics. Br J Cancer (2007) 0.75

The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine. Front Oncol (2015) 0.75

A high-content image analysis approach for quantitative measurements of chemosensitivity in patient-derived tumor microtissues. Sci Rep (2017) 0.75

Articles cited by this

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85

Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40

Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 12.35

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol (2005) 5.63

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol (2004) 4.77

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res (2006) 4.62

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol (2006) 4.58

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 4.06

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2004) 3.54

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol (2005) 2.95

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2006) 2.60

Assessing EGFR mutations. N Engl J Med (2006) 1.83

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res (2006) 1.53

EGFR mutation and response of lung cancer to gefitinib. N Engl J Med (2005) 1.42

Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol (2006) 1.40

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet (2004) 1.35

Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci (2007) 1.24

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer (2005) 1.07

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer (2005) 1.06

Articles by these authors

(truncated to the top 100)

Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20

Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97

Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res (1992) 1.72

Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res (2000) 1.64

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene (1992) 1.63

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63

Inflammatory pseudotumor of the lung in adults: radiographic and clinicopathological analysis. Ann Thorac Surg (1989) 1.53

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst (1993) 1.50

Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res (1999) 1.47

High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene (1992) 1.41

Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res (1996) 1.41

Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res (1990) 1.33

Polymorphism at codon 213 within the p53 gene. Oncogene (1991) 1.30

Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg (2001) 1.22

Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg (1990) 1.20

Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J (2011) 1.16

Mutations in the p53 gene in primary human breast cancers. Cancer Res (1991) 1.15

Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol (2007) 1.15

Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer (2000) 1.15

A clinicopathological study of gastric cancer with special reference to age of the patients: an analysis of 1,630 cases. World J Surg (1989) 1.13

Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer (1991) 1.09

Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res (1996) 1.07

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer (1997) 1.05

Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer (2001) 1.04

High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res (2000) 1.04

Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas. Br J Cancer (2001) 1.03

Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest (1995) 0.98

Malignant transformation of an intrathoracic neurofibroma in von Recklinghausen's disease. Scand Cardiovasc J (1998) 0.97

Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene (1998) 0.97

p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest (1994) 0.96

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer (2007) 0.96

p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res (1998) 0.94

Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health (1995) 0.94

Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am J Pathol (2001) 0.93

A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene (1993) 0.92

Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res (1995) 0.92

Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Ann Thorac Surg (2000) 0.91

Population-based mapping of pulmonary adenoma susceptibility 1 locus. Cancer Res (2000) 0.91

Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res (1997) 0.90

Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest (1992) 0.90

Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene (2007) 0.90

Surgical resection for pulmonary metastases of sweat gland carcinoma. Thorax (1994) 0.89

MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg (1999) 0.89

Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg (1997) 0.89

Surgical treatment of lung cancer in the octogenarian. Ann Thorac Surg (1994) 0.88

Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg (1997) 0.87

Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with non-small cell lung cancer. Surg Oncol (1996) 0.87

p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer (1998) 0.87

Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer (1998) 0.86

Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res (1997) 0.86

Frameshift mutations in TGFbetaRII, IGFIIR, BAX, hMSH3 and hMSH6 are absent in lung cancers. Carcinogenesis (1999) 0.86

Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J Clin Invest (1992) 0.85

Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study. Br J Cancer (1991) 0.84

Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res (1996) 0.83

Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res (1996) 0.83

Giant hamartoma of the lung with a high production of carbohydrate antigen 19-9. Ann Thorac Surg (1993) 0.83

N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res (1997) 0.83

Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type IV collagenase leads to an invasive phenotype. Biochem Biophys Res Commun (1991) 0.83

Combined resections of the diaphragm and the liver for a locally advanced non-small-cell lung cancer. Respiration (1996) 0.83

Frequent loss of the short arm of chromosome 9 in resected non-small-cell lung cancers from Japanese patients and its association with squamous cell carcinoma. J Cancer Res Clin Oncol (1995) 0.82

Polymorphism at codon 36 of the p53 gene. Oncogene (1994) 0.82

Pulmonary dirofilariasis causing a solitary lung mass and pleural effusion. Thorax (1991) 0.82

Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene (2012) 0.81

Maximum length of tracheal autografts in dogs. J Thorac Cardiovasc Surg (1993) 0.81

fos oncogene transfer to a transformed rat fibroblast cell line enhances spontaneous lung metastasis in rat. Jpn J Cancer Res (1986) 0.80

Angiosarcoma of the chest wall with a gastric metastasis. Thorac Cardiovasc Surg (1993) 0.80

[Delayed traumatic hernia diagnosed with magnetic resonance imaging]. Nihon Kyobu Shikkan Gakkai Zasshi (1997) 0.80

p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J Oncol (1997) 0.80

p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med (1998) 0.79

Topographical distributions of allelic loss in individual non-small-cell lung cancers. Am J Pathol (2000) 0.79

Effects of sodium n-butyrate on entry into S phase in resting rat 3Y1 cells infected with simian virus 40. J Virol (1985) 0.79

Lung adenocarcinoma is more sensitive than gastric adenocarcinoma to anticancer drugs in vitro. Eur J Surg Oncol (1991) 0.79

Selective cytotoxicity of phospholipids and diacylglycerols to rat 3Y1 fibroblasts transformed by adenovirus type 12 or its E1A gene. Cancer Res (1988) 0.78

Time to first cigarette and lung cancer risk in Japan. Ann Oncol (2013) 0.78

CT and MRI manifestations of primary pulmonary plasmacytoma. Clin Imaging (1995) 0.78

Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. Biol Trace Elem Res (1994) 0.78

Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg (2001) 0.78

Video-assisted thoracoscopic surgery of bullous and bleb disorders of the lung using endoscopic stapling device. Surg Laparosc Endosc (1995) 0.78

Transformation by v-H-ras does not restore proliferation of a set of temperature-sensitive cell-cycle mutants of rat 3Y1 fibroblasts. Cell Struct Funct (1990) 0.78

Hepatic inflow vessels caliber as an index for liver function. Hepatogastroenterology (1996) 0.78

Estradiol sensitivity test using contact-sensitive plates of confluent BALB/c 3T3 cell monolayers. Cancer Res (1990) 0.77

Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer (1994) 0.77

Thoracoscopy in the management of intrathoracic neurogenic tumors. Int Surg (1997) 0.77

Abortive transformation of temperature-sensitive mutants of rat 3Y1 cells by simian virus 40: effect of cellular arrest states on entry into S phase and cellular proliferation. J Cell Physiol (1985) 0.77

Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses. Tissue Antigens (2004) 0.77

Large cell carcinoma of the lung. Prognostic implications of histopathologic and immunohistochemical subtyping. Am J Clin Pathol (1990) 0.76

A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204). Br J Cancer (2008) 0.76

[Serum levels of c-erbB-2 protein in patients with lung adenocarcinoma: preliminary report]. Nihon Geka Gakkai Zasshi (1993) 0.75

Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer. Am J Clin Oncol (1997) 0.75

Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg Oncol (1995) 0.75

[A case of postoperative hyponatremia caused by Sheehan syndrome associated with lung carcinoma]. J UOEH (1995) 0.75

[A carcinoma arising from benign pleomorphic adenoma of the trachea]. Kyobu Geka (1997) 0.75

Papillary carcinoma in a huge intrathoracic goiter with tracheal stenosis and invasion. Case report. Scand J Thorac Cardiovasc Surg (1993) 0.75

[Surgical problems encountered in cases of S0 (serosal invasion-free) gastric cancers]. Gan No Rinsho (1988) 0.75

The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung. Eur J Surg Oncol (1995) 0.75

Characteristics of non-small cell lung cancer 3 cm or less in diameter. J Surg Oncol (1995) 0.75

Nucleolar organizer regions are independently associated with a shortened survival in patients with non-small cell lung cancer. Surg Oncol (1993) 0.75

Combined thoracoscopy and mediastinoscopy for the evaluation of mediastinal lymph node metastasis in left upper lobe lung cancer. J Cardiovasc Surg (Torino) (1994) 0.75

[Expression of CD44 alternative splicing variants in lung cancer]. Nihon Rinsho (1995) 0.75

Survival following resection for lung cancer as a second primary cancer. Int Surg (1996) 0.75